Cargando…
No evidence for cardiotoxicity of miltefosine – Reply()
Autores principales: | Barroso, Daniel Holanda, Gomes, Ciro Martins, Silva, Antônia Marilene da, Sampaio, Raimunda Nonata Ribeiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Dermatologia
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263635/ https://www.ncbi.nlm.nih.gov/pubmed/35667981 http://dx.doi.org/10.1016/j.abd.2022.03.001 |
Ejemplares similares
-
Comparison of cardiotoxicity between N-methyl-glucamine and miltefosine in the treatment of American cutaneous leishmaniasis()()
por: Barroso, Daniel Holanda, et al.
Publicado: (2021) -
No evidence for cardiotoxicity of miltefosine()
por: Dorlo, Thomas P.C.
Publicado: (2022) -
A Pilot Randomized Clinical Trial: Oral Miltefosine and Pentavalent Antimonials Associated With Pentoxifylline for the Treatment of American Tegumentary Leishmaniasis
por: Martins, Sofia Sales, et al.
Publicado: (2021) -
Meglumine antimoniate was associated with a higher cure rate than liposomal amphotericin B in the treatment of American tegumentary leishmaniasis: A retrospective cohort study from a Leishmania braziliensis-endemic area
por: Barroso, Daniel Holanda, et al.
Publicado: (2022) -
A retrospective cohort study of the effectiveness and adverse events of intralesional pentavalent antimonials in the treatment of cutaneous leishmaniasis
por: Rodrigues, Bruna Côrtes, et al.
Publicado: (2020)